Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 9/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.34 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18675868 | 0.75 | HSP90AA1 (0.47) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL30534095 | 0.74 | PDPK1 (0.56) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL102331 | 0.72 | PDPK1 (0.59) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL3799812 | 0.71 | SPHK2 (0.56) | HSP90AA1ADORA2AADORA1PDPK1ADORA3 | |
| SCHEMBL28231871 | 0.71 | ADORA2A (0.46) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL29471933 | 0.71 | ADORA2A (0.43) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL30632310 | 0.70 | PDPK1 (0.56) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL28154527 | 0.70 | PDPK1 (0.56) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL31556353 | 0.70 | PDPK1 (0.56) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 | |
| SCHEMBL15888379 | 0.67 | ADORA2A (0.46) | LOXL2HSP90AA1ADORA2AADORA1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190117683-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2019-04-25 | — | — | US | claimed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | claimed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | claimed |
| WO-2017060388-A1 | ALGINATE OLIGOMERS FOR THE TREATMENT OR PREVENTION OF MICROBIAL OVERGROWTH IN THE INTESTINAL TRACT | ALGIPHARMA AS (NO) | 2017-04-13 | — | — | WO | claimed |
| WO-2016151051-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2016-09-29 | — | — | WO | claimed |
| EP-3273995-B1 | COMBINED USE OF ALGINATE OLIGOMERS AND THE CFTR MODULATOR LUMACAFTOR IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-02-04 | — | — | US | disclosed |
| EP-3768323-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2021-01-27 | — | — | EP | disclosed |
| US-10751363-B2 | Use of aliginate oligomers and CFTR modulators in treatment of conditions associated with CFTR dysfunction | ALGIPHARMA AS (NO) | 2020-08-25 | — | — | US | disclosed |
| WO-2019180047-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | ALGIPHARMA AS (NO) | 2019-09-26 | — | — | WO | disclosed |
| US-20180055873-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-03-01 | — | — | US | disclosed |
| EP-3273995-A1 | USE OF ALGINATE OLIGOMERS AND CFTR MODULATORS IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH CFTR DYSFUNCTION | ALGIPHARMA AS (NO) | 2018-01-31 | — | — | EP | disclosed |
| EP-2152266-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | Ironwood Pharmaceuticals, Inc. (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2006101740-A3 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | UNIV CALIFORNIA (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-25 | — | — | US | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| EP-1863522-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863522-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006101740-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006101740-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030891-A1 | USE OF ALGINATE OLIGOMERS TO ENHANCE THE TRANSLOCATION OF MICRO/NANOPARTICLES ACROSS MUCUS LAYERS | MUC1, ALG1, ST3GAL3 | LOXL2 937/4885HSP90AA1 3112/4885ADORA2A 2790/4885 |
| US-20080318984-A1 | Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof | CFTR, ABCC5, QPCT | LOXL2 4513/4885HSP90AA1 2893/4885ADORA2A 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.